PalamarJJFitzgeraldNDGrundyDJ. Characteristics of poisoning involving ketamine in the United States, 2019-2021. I Psychopharmacol. 2022; 2698811221140006. doi:10.1177/02698811221140006
4.
HasinDSWallMMChoiCJ. State cannabis legalization and cannabis use disorder in the US Veterans Health Administration, 2015-2019. JAMA Psychiatry. 2023;80(4)380–388. doi:10.1001/jamapsychiatry.2023.0019
5.
HasinDSSarvetAL, CerdáM, . US adult illicit cannabis use, cannabis use disorder, and medical marijuana laws: 1991-1992 to 2012-2013. JAMA Psychiatry. 2017;74(6)579–588. doi:10.1001/jamapsychiatry.2017.0724
6.
SarvetAL, WallMM, KeyesKM, . Recent rapid decrease in adolescents’ perception that marijuana is harmful, but no concurrent increase in use. Drug Alcohol Depend. 2018; 186: 68–74. doi:10.1016/j.dragalcdep.2017.12.041
7.
FergussonDMBodenIMHorwoodLJ. Cannabis use and other illicit drug use: testing the cannabis gateway hypothesis. Addiction. 2006;101(4)556–569. doi:10.1111/j.l360-0443.2005.01322.x
8.
OlfsonMWallMMLiuSM. Cannabis use and risk of prescription opioid use disorder in the United States. Am I Psychiatry. 2018, 175(1):47–53. doi:10.1176/appi.ajp.2017.1704013
9.
WilliamsAR. Cannabis as a gateway drug for opioid use disorder. I Law Med Ethics. 2020;48(2)268–274.doi:10.1177/1073110520935338
10.
DarkeSDuflouJFarrellM. Characteristics and circumstances of death related to the self-administration of ketamine. Addiction. 2021;116(2)339–345. doi:10.1111/add.l5154